B+
Bull case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
MDAI
Spectral AIANasdaq / Health Care Equipment & Services
Last Price
$1.49+$0.11 (+7.97%)
At close · 2026-11-06
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+88.1
Score
AI commentary
Primary filing evidence supports tangible regulatory and launch milestones, but forward visibility remains limited because Spectral AI is only beginning commercial execution. The September 15 Form 8-K furnished an investor presentation rather than reporting a new operating result, so it does not by itself change the thesis [#8-K-2026-09-15]. Recent coverage is sparse, and no reliable analyst-revision, post-event market-reaction, social-sentiment, options, or short-interest evidence was supplied. The deterministic prior remains negative across 5- to 120-day horizons, supporting cautious monitoring rather than an aggressive re-rating thesis. Unavailable sentiment measures are represented as neutral placeholders, not observations.
RankAlpha Sentiment Codex - 2026-09-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventUKCA label-expansion decisionHigh impact
Spectral AI targets expanded UKCA authorization by year-end 2026, potentially enabling sales in the United Kingdom, Australia, or Gulf Cooperation Council markets. Regulatory timing and subsequent commercial uptake remain uncertain [#SEC-8K-2026-08-12].
2026-12-31catalystFirst U.S. DeepView commercial salesHigh impact
FDA De Novo clearance permits U.S. commercial distribution, and Spectral AI targets its first DeepView commercial sales by year-end 2026. Achieving this would validate the transition from government-funded development to commercial execution, but hospital procurement timing and initial demand remain unproven [#SEC-8K-2026-08-12].
2026-12-31catalystTriage and treatment outcome study initiationHigh impact
The company plans to initiate a U.S. study in Q4 2026 to evaluate whether DeepView improves surgical precision, accelerates treatment decisions, and reduces length of stay. Initiation would advance the hospital-adoption evidence base, although no completion or readout date was supplied [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-20 • Updated nightlySource: Internal modelMethodology